Articular cartilage stem cell paste grafting

Hyalex Orthopaedics receives FDA Breakthrough Device Designation for novel HYALEX® Cartilage System

Retrieved on: 
Wednesday, July 7, 2021

LEXINGTON, Mass., July 7, 2021 /PRNewswire/ -- Hyalex Orthopaedics, Inc., announced that the HYALEX Cartilage System has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • LEXINGTON, Mass., July 7, 2021 /PRNewswire/ -- Hyalex Orthopaedics, Inc., announced that the HYALEX Cartilage System has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
  • The HYALEX Cartilage System is intended to repair cartilage defects and restore function for patients with loss of knee articular cartilage and bone requiring surgery.
  • Unlike other cartilage solutions requiring multiple surgeries and regeneration, HYALEX Cartilage is a biomimetic materials platform designed to provide a single-step, off-the-shelf, high strength, low friction, low wear solution.
  • Hyalex Orthopaedics has published evidence of preservation of the cartilage counter-face with its HYALEX Cartilage1 and is protected by more than 17 patents and trademarks worldwide.

Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration

Retrieved on: 
Monday, March 15, 2021

We anticipate initiating the Phase 1/2 trial in the second quarter of 2021 utilizing funding provided by the $2M grant from the Department of Defense.

Key Points: 
  • We anticipate initiating the Phase 1/2 trial in the second quarter of 2021 utilizing funding provided by the $2M grant from the Department of Defense.
  • Histogens human extracellular matrix, or hECM, is intended for regenerating hyaline cartilage for the treatment of articular cartilage defects with a novel malleable scaffold that stimulates the bodys own stem cells.
  • Studies conducted by outside experts have demonstrated thatHST-003is anti-inflammatory, angiogenic, and can stimulate the growth of stem cells in damaged areas to induce tissue regeneration.
  • The most extensive in vivo work in animals has focused on the regeneration of new hyaline cartilage and bone in full thickness knee injuries.

AlloSource's ProChondrix CR, Cryopreserved Osteochondral Allograft, To Be Featured At The British Patellofemoral Society Meeting

Retrieved on: 
Friday, January 15, 2021

During the session titled ProChondrix CR: Cryopreserved off-the-shelf Hyaline Cartilage Allograft.

Key Points: 
  • During the session titled ProChondrix CR: Cryopreserved off-the-shelf Hyaline Cartilage Allograft.
  • Dr. Argo, with Beacon Orthopaedics and Sports Medicine in Cincinnati, Ohio, will highlight his experience repairing osteochondral defects of the knee with AlloSource's allograft.
  • A potentially debilitating condition, chondral injuries are a common issue that affect nearly one million people in the United States annually.
  • "This meeting provides a great opportunity to share my experience with ProChondrix for cartilage defects in the knee," said Dr. Argo.

AlloSource Announces First Patients Complete 12-Month Milestone In ProChondrix CR Clinical Study For Cartilage Defects In The Knee

Retrieved on: 
Tuesday, November 17, 2020

A potentially debilitating condition, chondral injuries are a common issue that affect nearly one million people in the United States annually.

Key Points: 
  • A potentially debilitating condition, chondral injuries are a common issue that affect nearly one million people in the United States annually.
  • As the leader in the processing of cartilage tissue for joint repair, AlloSource is excited to focus on the long-term outcomes for cartilage defects in the knee using ProChondrix CR, a cryopreserved osteochondral allograft.
  • "Seeing these early results furthers our momentum to validate the impact ProChondrix CR has on healing cartilage defects in the knee," said Dr. Ross Wilkins, AlloSource Senior Medical Director.
  • "The preliminary outcomes using ProChondrix CR look favorable and motivate me to continue to be a part of this important research."

Histogen Announces $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee

Retrieved on: 
Wednesday, September 16, 2020

Regenerating uniform functional hyaline cartilage is critical to restoring normal function for military personnel and civilians alike.

Key Points: 
  • Regenerating uniform functional hyaline cartilage is critical to restoring normal function for military personnel and civilians alike.
  • Histogens HST-003 has demonstrated hyaline cartilage regeneration in three different in vivo animal models conducted by orthopedic experts.
  • Approximately 900,000 Americans are affected by knee cartilage injuries annually, with 200,000 requiring surgical interventioni.
  • The most extensive in vivo work in animals has focused on the regeneration of new hyaline cartilage and bone in full thickness knee injuries.

Impact of COVID-19 on the Worldwide Cartilage Repair Industry to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 13, 2020

The "Cartilage Repair (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cartilage Repair (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.
  • The model discusses in detail the impact of COVID-19 on the Cartilage Repair market for the year 2020 and beyond.
  • When deteriorated cartilage is not treated at the initial stage, it will augment and at last require knee replacement surgery.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Cartilage Repair market in the future.

AlloSource Announces Two-Year Shelf Life On ProChondrix CR Fresh Cryopreserved Osteochondral Allograft

Retrieved on: 
Tuesday, March 12, 2019

The two-year shelf life helps alleviate the challenges of a short placement timeline found with similar osteochondral allografts and provides surgeons with more flexibility for their patients.

Key Points: 
  • The two-year shelf life helps alleviate the challenges of a short placement timeline found with similar osteochondral allografts and provides surgeons with more flexibility for their patients.
  • "We are proud to support our surgeon customers and their patients by extending the shelf life of ProChondrix CR," said Corey Stone, AlloSource Vice President of Marketing and Strategy.
  • ProChondrix CR provides several crucial elements to encourage cartilage healing, including viable chondrocytes, an intact extracellular matrix and native growth factors.
  • Learn more about ProChondrix CR by visiting AlloSource at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting March 12-16 in Las Vegas, Nevada.

Cartilage Repair Market to Reach a Market Size of $6.4 Billion by 2024 - KBV Research

Retrieved on: 
Thursday, February 21, 2019

NEW DELHI, Feb. 21, 2019 /PRNewswire/ -- According to a new report Global Cartilage Repair Market , published by KBV research, The Global Cartilage Repair Market size is expected to reach $6.4 billion by 2024, rising at a market growth of 8.5% CAGR during the forecast period.

Key Points: 
  • NEW DELHI, Feb. 21, 2019 /PRNewswire/ -- According to a new report Global Cartilage Repair Market , published by KBV research, The Global Cartilage Repair Market size is expected to reach $6.4 billion by 2024, rising at a market growth of 8.5% CAGR during the forecast period.
  • The growth of the cartilage repair market can be attributed to changing lifestyle, leading to a number of disorders such as obesity and degenerative joint diseases.
  • The Intrinsic Repair Stimulus market dominated the Global Cartilage Repair Market by Treatment Type in 2017 and it is due to the extensive use of microfracture technique in cartilage repair surgeries.
  • The Hyaline Cartilage market dominated the Global Cartilage Repair Market by Application in 2017, and would achieve a market value of $3,393.1 million by 2024.

Cartilage Repair Market to Reach a Market Size of $6.4 Billion by 2024 - KBV Research

Retrieved on: 
Thursday, February 21, 2019

NEW DELHI, Feb. 21, 2019 /PRNewswire/ -- According to a new report Global Cartilage Repair Market , published by KBV research, The Global Cartilage Repair Market size is expected to reach $6.4 billion by 2024, rising at a market growth of 8.5% CAGR during the forecast period.

Key Points: 
  • NEW DELHI, Feb. 21, 2019 /PRNewswire/ -- According to a new report Global Cartilage Repair Market , published by KBV research, The Global Cartilage Repair Market size is expected to reach $6.4 billion by 2024, rising at a market growth of 8.5% CAGR during the forecast period.
  • The growth of the cartilage repair market can be attributed to changing lifestyle, leading to a number of disorders such as obesity and degenerative joint diseases.
  • The Intrinsic Repair Stimulus market dominated the Global Cartilage Repair Market by Treatment Type in 2017 and it is due to the extensive use of microfracture technique in cartilage repair surgeries.
  • The Hyaline Cartilage market dominated the Global Cartilage Repair Market by Application in 2017, and would achieve a market value of $3,393.1 million by 2024.